From confusion to clarity: RAS blockade in patients hospitalized with COVID-19.
作者信息
Geherty Raymond A, Sparks Matthew A
机构信息
Division of Nephrology, Department of Medicine, Duke University School of Medicine, Durham, North Carolina, USA.
Division of Nephrology, Department of Medicine, Duke University School of Medicine, Durham, North Carolina, USA; Renal Section, Durham Veterans Affairs Health Care System, Durham, North Carolina, USA.
出版信息
Kidney Int. 2021 May;99(5):1059-1061. doi: 10.1016/j.kint.2021.02.034. Epub 2021 Mar 19.
Abstract
摘要
相似文献
1
From confusion to clarity: RAS blockade in patients hospitalized with COVID-19.从困惑到明晰：新冠病毒病住院患者的肾素-血管紧张素系统阻断治疗
Kidney Int. 2021 May;99(5):1059-1061. doi: 10.1016/j.kint.2021.02.034. Epub 2021 Mar 19.
2
RAAS Blockade and COVID-19: Mechanistic Modeling of Mas and AT1 Receptor Occupancy as Indicators of Pro-Inflammatory and Anti-Inflammatory Balance.RAAS 阻断与 COVID-19：Mas 和 AT1 受体占有率的机械建模作为促炎和抗炎平衡的指标。
Clin Pharmacol Ther. 2021 Apr;109(4):1092-1103. doi: 10.1002/cpt.2177. Epub 2021 Mar 10.
3
Renin-angiotensin system blockers and COVID-19.肾素-血管紧张素系统阻滞剂与新型冠状病毒肺炎
BMC Med. 2021 Jun 4;19(1):136. doi: 10.1186/s12916-021-02012-6.
4
Renin-angiotensin system inhibitors in management of hypertension during the COVID-19 pandemic.肾素-血管紧张素系统抑制剂在 COVID-19 大流行期间高血压管理中的应用。
J Physiol Pharmacol. 2020 Apr;71(2). doi: 10.26402/jpp.2020.2.01. Epub 2020 Jul 2.
5
Correlation between renin-angiotensin system and Severe Acute Respiratory Syndrome Coronavirus 2 infection: What do we know?肾素-血管紧张素系统与严重急性呼吸综合征冠状病毒 2 感染的相关性：我们了解多少？
Eur J Pharmacol. 2020 Sep 15;883:173373. doi: 10.1016/j.ejphar.2020.173373. Epub 2020 Jul 15.
6
ACE2: from protection of liver disease to propagation of COVID-19.ACE2：从保护肝脏疾病到传播 COVID-19。
Clin Sci (Lond). 2020 Dec 11;134(23):3137-3158. doi: 10.1042/CS20201268.
7
Pharmacovigilance in patients with diabetes: A data-driven analysis identifying specific RAS antagonists with adverse pulmonary safety profiles that have implications for COVID-19 morbidity and mortality.糖尿病患者的药物警戒：一项数据驱动的分析，确定了具有不良肺部安全性特征的特定 RAS 拮抗剂，这些特征对 COVID-19 的发病率和死亡率有影响。
J Am Pharm Assoc (2003). 2020 Nov-Dec;60(6):e145-e152. doi: 10.1016/j.japh.2020.05.018. Epub 2020 Jun 1.
8
Effects of Angiotensin II Receptor Blockers and ACE (Angiotensin-Converting Enzyme) Inhibitors on Virus Infection, Inflammatory Status, and Clinical Outcomes in Patients With COVID-19 and Hypertension: A Single-Center Retrospective Study.血管紧张素 II 受体阻滞剂和 ACE（血管紧张素转换酶）抑制剂对 COVID-19 合并高血压患者病毒感染、炎症状态和临床结局的影响：一项单中心回顾性研究。
Hypertension. 2020 Jul;76(1):51-58. doi: 10.1161/HYPERTENSIONAHA.120.15143. Epub 2020 Apr 29.
9
Assessment of ACE inhibitors/angiotensin receptor blockers in COVID-19 patients.评估血管紧张素转换酶抑制剂/血管紧张素受体阻滞剂在新冠肺炎患者中的应用。
Am J Physiol Lung Cell Mol Physiol. 2020 Jul 1;319(1):L37-L38. doi: 10.1152/ajplung.00262.2020.
10
Determinants of healing among patients with coronavirus disease 2019: the results of the SARS-RAS study of the Italian Society of Hypertension.新冠肺炎患者的愈合相关因素：意大利高血压学会 SARS-RAS 研究结果。
J Hypertens. 2021 Feb 1;39(2):376-380. doi: 10.1097/HJH.0000000000002666.
Zotero 插件